Novavax Inc. (NSDQ:NVAX) touted data today from the second Phase II trial of its RSV F nanoparticle vaccine candidate in women of child-bearing age. The research was published in the journal Vaccine. Novavax’s nanomedicine vaccine is being developed to protect infants from the respiratory syncytial virus. The Gaithersburg, Md.-based company presented top-line data from the Phase […]
Diamyd CEO exits over board rift | Personnel moves
Diamyd Medical AB (OTC:DMYDY) and its CEO parted ways after the chief executive had a falling out with the company’s board.
Elisabeth Lindner left her position with the company "due to disagreement with the Board concerning certain important matters," the company said in prepared remarks.
MassDevice Network
@MassDevice
LinkedIn
YouTube